172 results on '"Tavel, Jorge"'
Search Results
2. The Quality of Informed Consent in a Clinical Research Study in Thailand
3. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
4. CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-Analysis of 3 Vanguard Studies
5. Guide to Major Clinical Trials of Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients: Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Nucleotide Reverse Transcriptase Inhibitors
6. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
7. Antiretroviral Drug Content in Products from Developing Countries
8. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
9. CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients
10. CD4⁺ T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation
11. A Randomized, Double-Blinded, Placebo-Controlled Trial of Intermittent Administration of Interleukin-2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus
12. Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
13. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies
14. In APRICOT and PARADIGM 99% of HIV-HCV coinfected patients with an SVR12 achieved an SVR24 validating SVR12 as an endpoint for trials in this population: 809
15. Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon α-2a (40KD) (P) and ribavirin (R) with or without mericitabine in HCV genotype (G)1-infected treatment-experienced patients with advanced hepatic fibrosis: 82
16. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study: 81
17. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
18. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection
19. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
20. Induction of prolonged survival of CD4+T lymphocytes by intermittent IL-2 therapy in HIV-infected patients
21. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection
22. Analysis of Generic Nevirapine Products in Developing Countries
23. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
24. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers
25. Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
26. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, A Monoclonal Antibody, Plus Oseltamivir in Patients Hospitalized with Severe Influenza A Infection
27. Therapeutic use of interleukin-2 in HIV-infected patients
28. Antiretroviral drug content in products from developing countries
29. Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
30. Reply to Hunsberger and Memoli, “Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat”
31. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model
32. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers
33. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
34. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
35. A Novel Ordinal Endpoint is Proposed to Evaluate Clinical Status Over Time in Hospitalized Patients with Influenza
36. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers
37. Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study
38. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults
39. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
40. CD4 T Cell Survival Following Intermittent IL-2 Therapy is Predictive of Increase in CD4 T Cell Count in HIV-Infected Patients
41. A randomized trial comparing concise and standard consent forms in the START trial.
42. What are biomarkers?
43. Interferon-α Produces Significant Decreases in HIV Load
44. The Effect of Continuous Versus Pericycle Antiretroviral Therapy on IL-2 Responsiveness
45. CD4+T Cell Responses to Interleukin‐2 Administration in HIV‐Infected Patients Are Directly Related to the Baseline Level of Immune Activation
46. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans
47. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in FCS in mice and humans (88.29)
48. Post-trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study
49. A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study
50. Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.